Open AccessDiscovery research and development history of the dopamine D 2 receptor partial agonists, aripiprazole and brexpiprazole
Author(s) -
Kikuchi Tetsuro,
Maeda Kenji,
Suzuki Mikio,
Hirose Tsuyoshi,
Futamura Takashi,
McQuade Robert D.
Publication year - 2021
Publication title -
neuropsychopharmacology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.661
H-Index - 13
ISSN - 2574-173X
DOI - 10.1002/npr2.12180
Subject(s) - aripiprazole , partial agonist , schizophrenia (object oriented programming) , dopamine receptor d2 , psychiatry , adjunctive treatment , medicine , psychology , antipsychotic , mania , major depressive disorder , bipolar disorder , pharmacology , agonist , dopamine , lithium (medication) , mood , receptor
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D 2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify ® ). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europe, Japan, and many other countries for several indications including schizophrenia, acute mania, adjunctive treatment of major depressive disorder (MDD), irritability associated with autistic disorder, and Tourette's disorder. Otsuka next developed brexpiprazole (Rexulti ® ), another D 2 receptor partial agonist, which was granted marketing approval in the United States in 2015 as adjunctive therapy in major depressive disorder and for the treatment of schizophrenia. In Japan, brexpiprazole also received approval as a treatment for schizophrenia in 2018. In this review, we describe Otsuka's research history and achievements over the preceding 40 years in the area of antipsychotic drug discovery for dopamine D 2 receptor partial agonists.